The human immunodeficiency virus type 1 ribosomal frameshifting site is an invariant sequence determinant and an important target for antiviral therapy

J Virol. 2004 Feb;78(4):2082-7. doi: 10.1128/jvi.78.4.2082-2087.2004.

Abstract

Human immunodeficiency virus type 1 (HIV-1) utilizes a distinctive form of gene regulation as part of its life cycle, termed programmed -1 ribosomal frameshifting, to produce the required ratio of the Gag and Gag-Pol polyproteins. We carried out a sequence comparison of 1,000 HIV-1 sequences at the slippery site (UUUUUUA) and found that the site is invariant, which is somewhat surprising for a virus known for its variability. This prompted us to prepare a series of mutations to examine their effect upon frameshifting and viral infectivity. Among the series of mutations were changes of the HIV-1 slippery site to those effectively utilized by other viruses, because such mutations would be anticipated to have a relatively mild effect upon frameshifting. The results demonstrate that any change to the slippery site reduced frameshifting levels and also dramatically inhibited infectivity. Because ribosomal frameshifting is essential for HIV-1 replication and it is surprisingly resistant to mutation, modulation of HIV-1 frameshifting efficiency potentially represents an important target for the development of novel antiviral therapeutics.

Publication types

  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Anti-HIV Agents / pharmacology*
  • Base Sequence
  • Cell Line
  • Frameshifting, Ribosomal* / drug effects
  • Fusion Proteins, gag-pol / chemistry*
  • Fusion Proteins, gag-pol / genetics
  • Fusion Proteins, gag-pol / metabolism
  • Gene Products, gag / chemistry
  • Gene Products, gag / genetics
  • Gene Products, gag / metabolism
  • HIV-1 / genetics*
  • HIV-1 / pathogenicity
  • HIV-1 / physiology
  • HeLa Cells
  • Humans
  • Molecular Sequence Data
  • Mutation
  • Virus Replication

Substances

  • Anti-HIV Agents
  • Fusion Proteins, gag-pol
  • Gene Products, gag